STAGE IV CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AJCC V8
Clinical trials for STAGE IV CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IV CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Radiation plus immunotherapy: a new hope for advanced head and neck cancer?
Disease control OngoingThis phase III trial compares the standard immunotherapy drug pembrolizumab alone versus pembrolizumab plus radiation therapy in 290 patients with metastatic head and neck cancer. The goal is to see if adding radiation improves overall survival. Participants receive pembrolizumab…
Matched conditions: STAGE IV CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AJCC V8
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental drug duo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests two drugs together—sonidegib and pembrolizumab—in 36 adults with advanced solid tumors that have spread. Sonidegib blocks a growth signal in cancer cells, while pembrolizumab helps the immune system attack the tumor. The main goals are to find the saf…
Matched conditions: STAGE IV CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AJCC V8
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Immunotherapy before surgery shows promise for head and neck cancer
Disease control OngoingThis phase II trial is testing whether giving the immunotherapy drug cemiplimab before surgery can help shrink tumors in people with stage II to IV head and neck skin cancer that can be removed. The study enrolled 44 participants and aims to see how many respond to the drug. If i…
Matched conditions: STAGE IV CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Cancer vaccine plus immunotherapy shows promise in Hard-to-Treat cancers
Disease control OngoingThis study combines the CIMAvax EGF vaccine with immunotherapy drugs (nivolumab or pembrolizumab) to treat advanced non-small cell lung cancer and squamous head and neck cancer. The vaccine aims to slow tumor growth, while the immunotherapy helps the immune system attack cancer c…
Matched conditions: STAGE IV CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC